Lung cancer and molecular targeted drugs [PDF]
, 2013 Kiura, Katsuyuki, Tanimoto, Mitsune
core +1 more source
Clinicopathological Features, Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase (ALK) Rearrangement-Based Survival of Patients With Advanced Non-small Cell Lung Cancer in a Tertiary Care Setting. [PDF]
CureusBin Naeem S +6 more
europepmc +1 more source
Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC. [PDF]
Mol Diagn Ther, 2021 Kuang Y +12 more
europepmc +1 more source
Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer [PDF]
, 2017 et al,, Govindan, Ramaswamy
core +1 more source
Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB-ALK rearrangement and KRAS G12C mutation by sintilimab combined with anlotinib. [PDF]
Front OncolHuang N, Qu T, Zhang C, Li J.
europepmc +1 more source
Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]
, 2018 Bradley, Jeffrey D, et al,
core +1 more source
PLCXD3-ALK, a novel ALK rearrangement in lung squamous cell carcinoma and its clinical responses to ALK inhibitors. [PDF]
J Thorac DisChen K +9 more
europepmc +1 more source
EML4-ALK rearrangement in primary malignant fibrous histiocytoma of the lung treated with alectinib: A case report. [PDF]
Front Oncol, 2022 Zhang S, Liao X, Chen J.
europepmc +1 more source
Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement. [PDF]
Onco Targets Ther, 2021 Liang L +6 more
europepmc +1 more source